NEW HAVEN, CT, USA, November 25, 2025

美国康涅狄格州纽黑文，2025年11月25日

/ Biotech Newswire /

/ 生物科技通讯 /

--

--

BioMed X

BioMed X

, a leading external innovation hub for pharma, announced today the launch of a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, Connecticut.

，一家领先的制药外部创新中心，今天宣布与艾伯维（AbbVie）合作开展一项新的研究项目，该项目将在康涅狄格州纽黑文的BioMed X研究所进行。

The topic of the new research project in the field of neuroscience is the development of “

神经科学领域新研究项目的主题是“

Circuit-Based Model Systems of Anhedonia

基于电路的快感缺失模型系统

.” Anhedonia, the diminished ability to experience pleasure, remains one of the most challenging and poorly treated symptoms of depression, as well as several other psychiatric conditions. Anhedonia involves a complex interplay of multiple neurotransmitter systems and interconnected brain regions including the mesocorticolimbic pathway. .

“快感缺失，即体验愉悦的能力减弱，仍然是抑郁症以及其他几种精神疾病中最棘手且治疗效果最差的症状之一。快感缺失涉及多种神经递质系统和相互关联的脑区之间的复杂相互作用，包括中皮质边缘通路。”

The focus of this collaboration will be on the identification of specific mechanisms that underpin this debilitating symptom, using patient-derived data to validate mechanistic insights wherever possible.

这项合作的重点将是确定导致这种衰弱症状的具体机制，并尽可能利用患者提供的数据来验证这些机制性的见解。

With their global call for applications, BioMed X and AbbVie invite researchers world-wide to submit bold proposals for innovative research projects aimed at uncovering the entangled microcircuits and molecular targets disrupted in anhedonia. Proposals that integrate interdisciplinary approaches, including neurobiology, molecular biology, AI/machine learning, and clinical data, will be prioritized..

通过全球范围的申请号召，BioMed X 和 AbbVie 邀请全球研究人员提交大胆的创新研究项目提案，旨在揭示与快感缺失相关的复杂微回路和分子靶点。将优先考虑整合跨学科方法的提案，包括神经生物学、分子生物学、人工智能/机器学习以及临床数据。

Interested researchers are invited to submit their project proposals via the BioMed X Career Space at

有兴趣的研究人员可通过BioMed X职业空间提交他们的项目提案。

https://career.bmedx.com/call/2025-NHV-C01

https://career.bmedx.com/call/2025-NHV-C01

by

通过

January 18, 2026

2026年1月18日

.

。

Mark Johnston, CEO of BioMed X USA, commented:

马克·约翰斯顿，BioMed X美国公司的首席执行官评论道：

'Partnering with AbbVie on this new anhedonia project allows us to combine expertise in neuroscience, molecular biology, and clinical translation. Together, we aim to tackle the fundamental mechanisms of anhedonia, which could have profound implications for the treatment of depression and other related disorders.'.

“与艾伯维合作开展这项新的快感缺失项目，使我们能够结合神经科学、分子生物学和临床转化方面的专业知识。我们将共同致力于解决快感缺失的基本机制，这可能对抑郁症及其他相关疾病的治疗产生深远的影响。”

This represents the third research project in the collaboration between BioMed X and AbbVie, which started in 2015 with a research group in the field of Alzheimer’s disease at the BioMed X Institute in Heidelberg, Germany. More recently, in 2023, the partners launched their first U.S.-based project in New Haven focused on immunology and tissue engineering..

这代表着BioMed X与AbbVie之间合作的第三个研究项目。双方的合作始于2015年，在德国海德堡的BioMed X研究所成立了针对阿尔茨海默病的研究小组。最近，在2023年，合作伙伴在美国纽黑文启动了首个基于美国的项目，聚焦于免疫学和组织工程。

For high resolution please click the image.

请点击图像以获得高分辨率。

About

关于

BioMed X

BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, women’s health, cardiometabolic diseases, platform technologies, and artificial intelligence.

BioMed X 是一家独立研究机构，在德国海德堡、康涅狄格州纽黑文、康涅狄格州里奇菲尔德的 XSeed 实验室以及全球范围内的合作伙伴地点设有站点。我们立足于学术界和工业界之间的交界面，专注于肿瘤学、免疫学、神经科学、女性健康、心代谢疾病、平台技术及人工智能领域的生物医学研究与药物发现及开发。

.

。

All our research projects are supported by leading pharmaceutical companies or other external funding sources and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research..

我们所有的研究项目都受到领先的制药公司或其他外部资金来源的支持，并由从世界各地最优秀的学校招聘的早期职业科学家开展。通过将全球众包与本地孵化最优秀的人才和创意相结合，我们能够解决生物医学研究中最大的挑战。

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

我们致力于自由、创造性和好奇心驱动的研究，并结合对结果、时间表和可交付成果的严格验证。我们通过利用协同效应并促进跨学科的交叉融合，在推动转化生物医学方面发挥着巨大的作用。

Contact

联系

BioMed X Institute

生物医学X研究所

Maria Morganti

玛丽亚·莫甘蒂

VP, Head of Marketing & Communications

副总裁，市场营销与传播主管

+49 6221 42611 30

+49 6221 42611 30

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: International Cooperation; Academies and Institutes; Biomedical Research; early-career scientists; global crowdsourcing; Anhedonia; Depression; Neurobiology; Pleasure; Molecular Biology; Germany; BioMed X; neuroscience; AbbVie; collaborative research project; psychiatric conditions; neurotransmitter systems; brain regions; mesocorticolimbic pathway; global call for applications; research proposals; Mark Johnston; treatment of depression.

关键词：国际合作；科学院与研究所；生物医学研究；早期职业科学家；全球众包；快感缺失；抑郁症；神经生物学；愉悦；分子生物学；德国；BioMed X；神经科学；艾伯维；合作研究项目；精神疾病；神经递质系统；大脑区域；中皮质边缘通路；全球征集申请；研究提案；马克·约翰斯顿；抑郁症治疗。

Source: Biotech Newswire

来源：生物技术新闻社